A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Bioeconomy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Janssen Pharmaceutical Advances Rare Disease Research and Gene Therapy, Gains Breakthrough Designation in China

Janssen Pharmaceutical Companies Secures FDA Approval for NSCLC Therapy and Champions Cardiac Health Equity

Janssen Pharmaceutical Drives Industry Innovation with New Ulcerative Colitis Research, Gene Therapy Discussions, Advances in Lung Cancer Therapeutics, and Initiatives on Health Equity

CHMP recommends approval of Janssen's CARVYKTI cilta-cel for earlier treatment of relapsed and refractory multiple myeloma; this marks the first time a CAR-T therapy has received a positive CHMP opinion for this patient population post first relapse

FDA approves J&J's supplemental application for a reduced dosing regimen of TECVAYLI, an injectable medicine for patients with relapsed or refractory multiple myeloma; the approval will enable biweekly, weight-based dosing, adding flexibility for patients

Ask us about our Bioeconomy market view

Trending Chart

Interactive chart with headline count